{"nctId":"NCT03429543","briefTitle":"Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM","startDateStruct":{"date":"2018-03-20","type":"ACTUAL"},"conditions":["Diabetes Mellitus, Type 2"],"count":175,"armGroups":[{"label":"Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ Mono","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Metformin","Drug: Insulin","Drug: Placebo"]},{"label":"Placebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin","Drug: Insulin","Drug: Placebo","Drug: Linagliptin"]},{"label":"Placebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin","Drug: Insulin","Drug: Placebo","Drug: Empagliflozin"]},{"label":"Placebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin","Drug: Insulin","Drug: Placebo","Drug: Empagliflozin"]},{"label":"Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin","Drug: Insulin","Drug: Linagliptin"]},{"label":"Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin","Drug: Insulin","Drug: Empagliflozin"]},{"label":"Empagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin","Drug: Insulin","Drug: Empagliflozin"]}],"interventions":[{"name":"Metformin","otherNames":[]},{"name":"Insulin","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Linagliptin","otherNames":["Trajenta(R)"]},{"name":"Empagliflozin","otherNames":["Jardiance(R)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients aged 10 to 17 years (inclusive) at the time of randomisation (Visit 2)\n* Male and female patients\n* Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient's legal representative information sheet.\n* Signed and dated written informed consent provided by the patient's parent(s) (or legal guardian) and patient's assent in accordance with ICH-GCP and local legislation prior to admission to the trial (informed assent will be sought according to the patient's age, level of maturity, competence and capacity)\n* Documented diagnosis of T2DM at Visit 1A:\n\n  * DINAMO TM: Documented diagnosis of T2DM for at least 8 weeks at Visit 1A\n  * DINAMO TM Mono: Confirmation of T2DM at Visit 1A\n* Insufficient glycaemic control as measured by the central laboratory at Visit 1A:\n\n  * DINAMO TM: HbA1c ≥ 6.5% and ≤ 10.5%\n  * DINAMO TM Mono: HbA1c ≥ 6.5% and ≤ 9.0%\n* DINAMO TM: Patients treated with\n\n  * diet and exercise plus metformin at a stable dose for 8 weeks prior to Visit 2 or not tolerating metformin (defined as patients who were on metformin treatment for at least 1 week and had to discontinue metformin due to metformin-related side effects as assessed by the investigator) AND/OR\n  * diet and exercise plus stable basal or MDI insulin therapy,, defined as a weekly average variation of the basal insulin dose ≤ 0.1 IU/kg over 8 weeks prior to Visit 2. - DINAMOTM Mono: Drug-naïve patients or patients not on active treatment (including discontinuation of metformin due to intolerance \\[or previous discontinuation for other reasons\\] and/or discontinuation of insulin \\[insulin use must be 8 weeks or less\\] at investigator's discretion) prior to or at Visit 1A)\n* BMI ≥ 85th percentile for age and sex according to WHO references at Visit 1B\n* Non-fasting serum C-peptide levels ≥ 0.6 ng/ml as measured by the central laboratory at Visit 1A\n* Compliance with trial medication intake must be between 75% and 125% during the open-label placebo run-in period\n* Further inclusion criteria apply\n\nExclusion Criteria:\n\n* Any history of acute metabolic decompensation such as diabetic ketoacidosis within 8 weeks prior to Visit 1A and up to randomisation (mild to moderate polyuria at the time of randomisation is acceptable)\n* Diagnosis of monogenic diabetes (e.g. MODY)\n* History of pancreatitis\n* Diagnosis of metabolic bone disease\n* Gastrointestinal disorders that might interfere with study drug absorption according to investigator assessment\n* Secondary obesity as part of a syndrome (e.g. Prader-Willi syndrome)\n* Any antidiabetic medication (with the exception of metformin and/or insulin background therapy) within 8 weeks prior to Visit 1A and until Visit 2\n* Treatment with weight reduction medications (including anti-obesity drugs) within 3 months prior to Visit 1A and until Visit 2\n* History of weight-loss surgery or current aggressive diet regimen (according to investigator assessment) at Visit 1A and until Visit 2\n* Treatment with systemic corticosteroids for \\> 1 week within 4 weeks prior to Visit 1A and up to Visit 2 Inhaled or topical use of corticosteroids (e.g. for asthma/chronic obstructive pulmonary disease) is acceptable.\n* Change in dose of thyroid hormones within 6 weeks prior to Visit 1A or planned change or initiation of such therapy before Visit 2\n* Known hypersensitivity or allergy to the investigational products or their excipients\n* Impaired renal function defined as estimated Glomerular Filtration Rate (eGFR) \\< 60 ml/min/1.73m² (according to Zappitelli formula) as measured by the central laboratory at Visit 1A\n* Indication of liver disease defined by serum level of either alanine transaminase (ALT), aspartate transaminase (AST) or alkaline phosphatase above 3 fold upper limit of normal (ULN) at Visit 1A as measured by the central laboratory at Visit 1A\n* History of belonephobia (needle phobia)\n* Any documented active or suspected malignancy or history of malignancy within 5 years prior to Visit 1A, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix\n* Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells (e.g. malaria, babesiosis, haemolytic anaemia)\n* Any other acute or chronic medical or psychiatric condition or laboratory abnormality that, based on investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcome\n* Medical contraindications to metformin according to the local label (for patient on metformin background therapy)\n* Patient not able or cannot be supported by his/her parent(s) or legal guardian to understand and comply with study requirements based on investigator's judgement\n* Previous randomisation in this trial\n* Currently enrolled in another investigational device or drug trial, or less than 30 days since ending another investigational device or drug trial(s), or receiving other investigational treatment(s)\n* Chronic alcohol or drug abuse within 3 months prior to Visit 1A or any condition that, in the investigator's opinion, makes them an unreliable trial patient or unlikely to complete the trial\n* Female patients who are pregnant, nursing, or who plan to become pregnant in the trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Glycated Haemoglobin (HbA1c) (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ","description":"Adjusted means taken from the following three models, as pre-specified in the protocol:\n\nTreatment group 1 (TG1): \\[Placebo\\], \\[Linagliptin 5mg\\] and \\[Empagliflozin pooled\\] Treatment group 2 (TG2): \\[Placebo\\] and \\[Empagliflozin 10mg and 10+25mg\\] Treatment group 3 (TG3): \\[Placebo\\] and \\[Empagliflozin 10mg\\]\n\nANCOVA with continuous covariate (baseline HbA1c) and categorical covariates (treatment \\& age). Effect of linagliptin and of empagliflozin was compared with placebo at an overall α of 0.05 (2-sided) using the Hochberg method to account for multiple testing.\n\nAfter having obtained statistically significant results for both hypotheses of the primary family of hypotheses (TG1), the secondary hypotheses were to compare the individual empagliflozin doses versus placebo (TG2 \\& TG3). ANCOVA utilized a weight of zero for patients who were not in the hypothesis test of interest, a value of 2 for re-randomised patients who were in the hypothesis test of interest and a value of 1 otherwise.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"0.33","spread":null},{"groupId":"OG002","value":"-0.17","spread":null},{"groupId":"OG003","value":"-0.49","spread":null},{"groupId":"OG004","value":"0.14","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With Treatment Failure up to or at Week 26","description":"Percentage of patients with treatment failure up to or at Week 26 as a binary endpoint, defined as meeting at least one of the following criteria:\n\n* Use of rescue medication at any time up to Week 26\n* Increase from baseline in HbA1c by 0.5% at Week 26 . Increase from baseline in HbA1c to above 7.0% at Week 26 in patients with baseline HbA1c \\<7.0%","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ Mono","description":"Change in Glycated haemoglobin (HbA1c) (%) from baseline to the end of 26 weeks. Adjusted values came from a restricted maximum likelihood (REML) approach with mixed model for repeated measures (MMRM). Analyses included fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as the repeated measure with an unstructured covariance structure used to model the within-patient measurements.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":null},{"groupId":"OG001","value":"-0.53","spread":null},{"groupId":"OG002","value":"-0.23","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Treatment Failure","description":"Time to treatment failure was analysed by Kaplan-Meier estimates up to the end of the study (Week 52). Patients in the placebo group were censored after 26 weeks unless a prior treatment failure was observed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.600","spread":"19.941"},{"groupId":"OG001","value":"72.167","spread":"20.280"},{"groupId":"OG002","value":"167.333","spread":"26.711"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG, mg/dL) From Baseline to the End of 26 Weeks","description":"Change in fasting plasma glucose (FPG, Milligrams Per Deciliter (mg/dL)) from baseline to the end of 26 weeks. Adjusted values taken from analysis of covariance (ANCOVA) model with treatment as a fixed classification effect, baseline FPG as linear covariate and age at randomisation as categorical covariate. The random error was assumed to be normally distributed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.70","spread":null},{"groupId":"OG001","value":"10.29","spread":null},{"groupId":"OG002","value":"-19.48","spread":null},{"groupId":"OG003","value":"-38.50","spread":null},{"groupId":"OG004","value":"0.12","spread":null},{"groupId":"OG005","value":"-18.45","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (kg) From Baseline to the End of 26 Weeks","description":"Change in body weight (kg) from baseline to the end of 26 weeks. Adjusted values taken from mixed model for repeated measures (MMRM) with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as repeated measure with an unstructured covariance structure used to model the within-patient measurements.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":null},{"groupId":"OG001","value":"1.42","spread":null},{"groupId":"OG002","value":"-0.79","spread":null},{"groupId":"OG003","value":"2.64","spread":null},{"groupId":"OG004","value":"2.69","spread":null},{"groupId":"OG005","value":"1.29","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure (SBP, mmHg) From Baseline to the End of 26 Weeks","description":"Change in systolic blood pressure (SBP, millimeters of mercury (mmHg)) from baseline to the end of 26 weeks. Adjusted values taken from mixed model for repeated measures (MMRM) with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as repeated measure with an unstructured covariance structure used to model the within-patient measurements.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":null},{"groupId":"OG001","value":"2.21","spread":null},{"groupId":"OG002","value":"-0.12","spread":null},{"groupId":"OG003","value":"2.63","spread":null},{"groupId":"OG004","value":"5.16","spread":null},{"groupId":"OG005","value":"2.63","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure (DBP, mmHg) From Baseline to the End of 26 Weeks","description":"Change in diastolic blood pressure (DBP, millimeters of mercury (mmHg)) from baseline to the end of 26 weeks. Adjusted values taken from mixed model for repeated measures (MMRM) with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as repeated measure with an unstructured covariance structure used to model the within-patient measurements.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":null},{"groupId":"OG001","value":"2.26","spread":null},{"groupId":"OG002","value":"0.78","spread":null},{"groupId":"OG003","value":"3.42","spread":null},{"groupId":"OG004","value":"6.75","spread":null},{"groupId":"OG005","value":"-3.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieve HbA1c <6.5% at the End of 26 Weeks","description":"Percentage of patients who achieve HbA1c \\<6.5% at the end of 26 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"15.4","spread":null},{"groupId":"OG002","value":"21.2","spread":null},{"groupId":"OG003","value":"40.0","spread":null},{"groupId":"OG004","value":"16.7","spread":null},{"groupId":"OG005","value":"16.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieve HbA1c <7.0% at the End of 26 Weeks","description":"Percentage of patients who achieve HbA1c \\<7.0% at the end of 26 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5","spread":null},{"groupId":"OG001","value":"26.9","spread":null},{"groupId":"OG002","value":"34.6","spread":null},{"groupId":"OG003","value":"40.0","spread":null},{"groupId":"OG004","value":"16.7","spread":null},{"groupId":"OG005","value":"66.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":58},"commonTop":["Hypoglycaemia","Headache","Vitamin D deficiency","Blood ketone body increased","Diarrhoea"]}}}